New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 1.5mg - film coated tablet - 1.5 mg - active: riociguat 1.5mg excipient: crospovidone hyprolose hypromellose   iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 2mg - film coated tablet - 2 mg - active: riociguat 2mg excipient: crospovidone hyprolose hypromellose   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - riociguat 2.5mg - film coated tablet - 2.5 mg - active: riociguat 2.5mg excipient: crospovidone hyprolose hypromellose   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

Israel - English - Ministry of Health

taro international ltd, israel - abacavir; lamivudine - film coated tablets - lamivudine 300 mg; abacavir 600 mg - lamivudine and abacavir - abacavir lamivudine taro is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.

Ireland - English - HPRA (Health Products Regulatory Authority)

merus labs luxco ii s.à.r.l. - isosorbide dinitrate - concentrate for solution for injection/infusion - 1 milligram(s)/millilitre - organic nitrates; isosorbide dinitrate

Ireland - English - HPRA (Health Products Regulatory Authority)

merus labs luxco ii s.à.r.l. - glyceryl trinitrate - solution for infusion - 1 milligram(s)/millilitre - organic nitrates; glyceryl trinitrate

Ireland - English - HPRA (Health Products Regulatory Authority)

merus labs luxco ii s.à.r.l. - glyceryl trinitrate - solution for infusion - 1 milligram(s)/millilitre - organic nitrates; glyceryl trinitrate

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: macrogol 8000; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose - sildenafil is used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil has not been evaluated in patients currently on bosentan therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; calcium hydrogen phosphate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer ag, germany - riociguat - film-coated tablet - 0.5 mg